β Scribed by Clark, K. Reed
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Gene therapy is a promising clinical tool that is no longer limited as a method to supplement genetic deficits, but rather is considered reliable for delivering proteins to specific tissues or cells. Recombinant adenoβassociated virus (rAAV) vector is one of the most potent gene transfe
## Abstract Vectors derived from adenoβassociated virus type 2 (AAV2) are promising gene delivery vehicles, but it is still challenging to get the large number of recombinant adenoβassociated virus (rAAV) particles required for large animal and clinical studies. Current transfection technology requ
Recombinant adeno-associated virus 2 (AAV) vectors have proven to be a potentially useful alternative to the more commonly used retroviral and adenoviral vectors for gene therapy in humans. Their safety and efficacy in Phase I clinical trials for gene therapy of cystic fibrosis and hemophilia B have
## Abstract ## Background Gene transfer to salivary glands (SGs) can be accomplished in a minimally invasive manner, resulting in stable, longβterm secretion of the transgene product. Therefore, SGs provide a novel target site for several potentially useful clinical gene therapeutics applications.